Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea

NCT00126399

Rosacea

COMPLETED PHASE3

Laboratory Characteristics in Chronic Atrophic Acrodermatitis

NCT02147262

Chronic Atrophic Acrodermatitis

UNKNOWN NA

Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?

NCT02688738

Propionibacterium

UNKNOWN NA

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

NCT02341209

Cutaneous T-cell Lymphoma Mycosis Fungoides Sezary Syndrome

TERMINATED PHASE2

Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis

NCT01205464

Fatigue Radicular Pain Cognitive Dysfunction +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rosacea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oracea®

Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules

Group Type ACTIVE_COMPARATOR

Doxycycline

Intervention Type DRUG

doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning

placebo

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Placebo, oral, one capsule daily in the morning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxycycline

doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning

Intervention Type DRUG

Placebo

Placebo, oral, one capsule daily in the morning

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oracea®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is male or female aged 18 to 70 years inclusive
* Subject with papulopustular rosacea (5 to 40 papules or pustules)

Exclusion Criteria

* Subject has any other active dermatological condition on face that may interfere with the conduct of the study
* Subject uses proton pump inhibitors for treatment of gastroesophageal reflux within 30 days prior to baseline visit or during the study
* Subject uses spironolactone within 30 days prior to baseline visit or during the study
* Subject requires chronic treatment (\>14 days) with sulfa drugs, erythromycin, cephalosporins and quinolones within 30 days prior to baseline visit or during the study
* Subject has used tetracycline antibiotics within 30 days prior to baseline visit or during the study
* Subject has used penicillin antibiotics within 30 days prior to baseline visit or during the study
* Subject uses topical or oral dapsone
* Subject has had a change in hormonal therapy within 3 months of initiation of therapy or during the study
* Subject has used systemic immunosuppressants (e.g. corticosteroids, cyclosporine, imuran, biologics, mycophenolate mofetil) within 30 days prior to baseline visit. For subjects who have received treatment with biologics, treatment must have been discontinued within 90 days prior to baseline
* Subject has used any systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit
* Subject has used systemic retinoids within 6 months of the baseline visit
* Subject takes niacin at a dosage of 500 mg or more per day
* Subject has used any topical rosacea therapy including topical antibiotics, topical retinoids, topical sodium sulfacetamide preparations, topical benzoyl peroxides, topical vasoconstricting agents (e.g., oxymetazoline) topical calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) within 30 days prior to baseline visit
* Subject has been treated with another investigational drug or device within 30 days of baseline visit. For subjects who received experimental biologic treatment, treatment must have been discontinued within five half lives of the baseline visit.
* Subject has a known allergy to any of the components of the study products, and/or a known hypersensitivity to tetracyclines
* Subject is using a clinically significant concomitant drug (e.g., use of long term non-steroidal anti-inflammatory agents unless used only on a PRN basis less than 7 days per month)
* Subject has used vasodilators or an adrenergic blocking agent within 6 weeks of baseline visit (except subjects on stable dose for greater than 3 months)
* Subject has had laser or light therapy on the face within 3 months of the baseline visit
* Subject with active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist
* Subject with rhinophymatous rosacea
* Subject with a history of noncompliance with a treatment regimen
* Subject is at risk in terms of precautions, warnings, and contraindications (see package insert)
* Subject has previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics
* Subjects with a recent history of alcohol and/or drug abuse

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No